Good morning. As AI becomes more widely used in health care, could it actually lead doctors to lose some of their skills? One ...

Stoke Therapeutics and Biogen have begun dosing in the global Phase III EMPEROR study of zorevunersen for Dravet syndrome, ...

Cambridge, Massachusetts Wednesday, August 13, 2025, 15:00 Hrs [IST] ...

Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...

Stoke Therapeutics ( ($STOK) ) has released its Q2 earnings. Here is a breakdown of the information Stoke Therapeutics presented to its investors.

The Brennan family will host the 7th Annual Dance for Dravet on September 26th at the Third Degree Glass Factory to raise ...

In the EMPEROR trial, children with a confirmed variant in the SCN1A gene not associated with gain-of-function mutations will receive zorevunersen or a placebo.

The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

August 5, 2025Harmony Biosciences Holdings, Inc. misses on earnings expectations. Reported EPS is $0.681 EPS, expectations ...

Ubwonko bw’umuntu, ku kigereranyo rusange, ni gacye cyane bushobora kurenza dogere celicius imwe (1C) ku gipimo umubiri wacu ...

As I filled out a waiver so he could enter the store’s small play area, I noticed I was the only parent present.” ...